wide open, wide open, wide open (someone poke Rod Dausch, please)........
Thursday February 10, 8:49 pm Eastern Time
Company Press Release
SOURCE: Abgenix, Inc.
Abgenix Announces the Sale of 3,000,000 Shares of
Common Stock in a Follow-On Public Stock Offering
Includes 840,000 Shares Sold by Cell Genesys
FREMONT, Calif., Feb. 10 /PRNewswire/ -- Abgenix, Inc. (Nasdaq: ABGX - news) today announced the public offering of
3,000,000 shares of Common Stock at a price of $210 per share.
Of the 3,000,000 shares of Common Stock offered, 2,160,000 were sold by the Company and 840,000 were sold by a
selling stockholder of the Company, Cell Genesys, Inc. (Nasdaq: CEGE - news). The shares were offered by an underwriting
group led by Robertson Stephens, Lehman Brothers Inc., Merrill Lynch & Co. and Pacific Growth Equities, Inc. The
underwriters have an option to purchase up to an additional 450,000 shares, of which 324,000 shares shall be from Abgenix
and 126,000 shares shall be from the selling stockholder, Cell Genesys, Inc.
(snip)
Thursday February 10, 8:37 pm Eastern Time
Company Press Release
SOURCE: Celgene Corporation
Celgene Corporation Prices Common Stock Offering
WARREN, N.J., Feb. 10 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG - news) today announced that it has priced
a public offering of 3,000,000 shares of its Common Stock at $101.00 per share. Of the shares offered, 2,484,000 shares are
being sold by Celgene for its own account. The remaining 516,000 shares are being sold on behalf of John Hancock Life
Insurance Company and its affiliates. Celgene has granted to the underwriters an option to purchase an additional 450,000
shares of common stock to cover over-allotments.
(snip)
Thursday February 10, 8:25 am Eastern Time
Company Press Release
SOURCE: Genzyme Transgenics Corporation
Genzyme Transgenics Announces Completion Of
Public Offering
FRAMINGHAM, Mass., Feb. 10 /PRNewswire/ -- Genzyme Transgenics Corporation (Nasdaq: GZTC - news) announced
today the completion of its previously announced public offering. Including the over-allotment, the Company sold 4,025,000
shares of its common stock at $20 per share. Net proceeds to the Company totaled approximately $75.7 million. The
Company now has approximately 27.8 million shares outstanding. The managing underwriters for the offering were Warburg
Dillon Read LLC and Chase H&Q.
(snip)
It is very, very frustrating to see the sector awash in this sort of liquidity, and to be an investor in a company where the CFO makes no effort to grab a single penny. |
